Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Acquires QuantaLife for $162M

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories today said that it has acquired digital PCR systems maker QuantaLife for $162 million in cash plus potential future milestone payments.

Pleasanton, Calif.-based QuantaLife sells the Droplet Digital (ddPCR) system, which is a high-resolution platform for validating next-generation sequencing discoveries. The platform can be used for detecting rare mutations, precise measurement of copy number variation, absolute quantification of gene expression, and for molecular diagnostic applications.

"This elegant solution expands the current state of the art methods of quantitative PCR, and we look forward to its adoption in life science research," Bio-Rad President and CEO Norman Schwartz said in a statement.

QuantaLife began commercial sales of the ddPCR system this past summer. The technology competes with digital PCR offerings sold by Life Technologies, RainDance Technologies, and Fluidigm.

Less than a year ago, QuantaLife raised $17.2 million a Series B financing round.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.